

Doç. Dr. MAZDAK GANJALI KHANI HAKEMI

Kişisel Bilgiler

E-posta: mazdak.ganjali@medipol.edu.tr

Web: <https://avesis.medipol.edu.tr/mazdak.hakemi>

Uluslararası Araştırmacı ID'leri

ScholarID: lx-IRFsAAAAJ

ORCID: 0000-0002-4764-7616

Publons / Web Of Science ResearcherID: JRX-1501-2023

ScopusID: 54412107500

Biyografi

Mazdak obtained his BSc degree in Medical Laboratory Sciences from Iran University of Medical Sciences in 1999. Subsequently, he pursued his MSc in Medical Immunology at Tehran University of Medical Sciences, completing the program in 2002. In 2006, Mazdak commenced his PhD program in Medical Immunology at Isfahan University of Medical Sciences, with a specific focus on cellular and molecular immunology. During the course of his doctoral studies, he spent a sabbatical period at Ludwig-Maximilian University in Munich, Germany. He successfully defended his PhD thesis in 2011.

He commenced his academic journey as an assistant professor at Isfahan University of Medical Sciences in Iran in 2011. Over the years, his dedication and contributions led to his appointment as an associate professor, a position he held from 2017 to 2022 at the same institution. Seeking new horizons, he transitioned to Yeditepe University in Istanbul, serving as a guest professor for 10 months. Subsequently, he joined Istanbul Medipol University as a member of [SABITA](#), marking the beginning of his current responsibilities.

Throughout his professional tenure, he has been actively involved in teaching diverse courses on Immunology and related disciplines for both undergraduate and graduate students. An integral part of his academic portfolio includes supervising over 60 Ph.D. and M.Sc. theses, alongside the publication of more than 140 peer-reviewed scientific articles in esteemed international journals. In addition, he has successfully obtained three national patents and authored 20 books. His research focus primarily centers around molecular immunology, with a specialization in cancer and autoimmune disorders, reflecting his commitment to advancing knowledge and contributing to the understanding of these critical fields.

Araştırma Alanları

Yaşam Bilimleri, Temel Bilimler

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy**
Abdolmaleki S., GANJALI KHANI HAKEMI M., Ganjalikhany M. R.
PLoS ONE, cilt.19, sa.7 July, 2024 (SCI-Expanded)

- II. **Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model**
Samman N, Mohabatkar H, Behbahani M, GANJALI KHANI HAKEMI M.
PLoS ONE, cilt.19, sa.6 June, 2024 (SCI-Expanded)
- III. **TIM-3/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1**
Shapourian H, Ghanadian M, Eskandari N, Shokouhi A, Demirel G. Y., Bazhin A. V., Ganjalikhani-Hakemi M.
BMC CANCER, cilt.24, sa.1, 2024 (SCI-Expanded)
- IV. **Bioactive peptides: an alternative therapeutic approach for cancer management**
Ghadiri N., Javidan M., Sheikhi S., Taştan Ö., Parodi A., Liao Z., Tayybi Azar M., Ganjalikhani-Hakemi M.
FRONTIERS IN IMMUNOLOGY, cilt.15, 2024 (SCI-Expanded)
- V. **Editorial: Immunologic tumor microenvironment modulators for turning “cold” tumors to “hot” tumors**
GANJALI KHANI HAKEMI M., Yanikkaya Demirel G., He X., Zeng C.
Frontiers in Immunology, cilt.15, 2024 (SCI-Expanded)
- VI. **PD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia**
Soltani M., Ghanadian M., Ghezelbash B., Shokouhi A., Zamyatnin A. A., Bazhin A. V., Ganjalikhani-Hakemi M.
BMC Cancer, cilt.23, sa.1, 2023 (SCI-Expanded)
- VII. **Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)**
Bakhtiari T., Ahmadvand M., Yaghmaie M., Sadeghi A., Mousavi S. A., Rostami T., Ganjalikhani-Hakemi M.
BMC Immunology, cilt.24, sa.1, 2023 (SCI-Expanded)
- VIII. **TIM-3/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines**
Rezaei M., Ghanadian M., Ghezelbash B., Shokouhi A., Bazhin A. V., Zamyatnin A. A., Ganjalikhani-Hakemi M.
FRONTIERS IN IMMUNOLOGY, cilt.14, 2023 (SCI-Expanded)
- IX. **PD-1/PD-L1 Interaction Regulates BCL2, KI67, BAX, and CASP3, Altering Proliferation, Survival, and Apoptosis in Acute Myeloid Leukemia**
Soltani M., Vosoughi M., Ganjalikhani-Hakemi M., Shapoorian H., Beshkar P., Eskandari N., Ghezelbash B.
Iranian Journal of Allergy, Asthma and Immunology, cilt.22, sa.5, ss.495-503, 2023 (SCI-Expanded)
- X. **Morphology-Dependent Immunomodulatory Coating of Hydroxyapatite/PEO for Magnesium-Based Bone Implants**
Farshid S., Kharaziha M., Salehi H., Ganjalikhani Hakemi M.
ACS APPLIED MATERIALS & INTERFACES, cilt.15, sa.42, ss.48996-49011, 2023 (SCI-Expanded)
- XI. **Non-infectious meningitis and CNS demyelinating diseases: A conceptual review**
Etemadifar M., Fereidan-Esfahani M., Sedaghat N., Kargaran P., Mansouri A., Abhari A., Aghababaei A., Jannesari A., Salari M., Ganjalikhani-Hakemi M., et al.
Revue Neurologique, cilt.179, sa.6, ss.533-547, 2023 (SCI-Expanded)
- XII. **Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy**
Ganjalikhani Hakemi M., Yanikkaya Demirel G., Li Y., Jayakumar N.
Frontiers in Immunology, cilt.14, 2023 (SCI-Expanded)
- XIII. **The Influence of KIR Gene Polymorphisms and KIR-ligand Binding on Outcomes in Hematologic Malignancies following Haploidentical Stem Cell Transplantation: A Comprehensive Review**
Bakhtiari T., Ahmadvand M., Salmaninejad A., Ghaderi A., Yaghmaie M., Sadeghi A., Mousavi S. A., Rostami T., Ganjalikhani-Hakemi M.
Current Cancer Drug Targets, cilt.23, sa.11, ss.868-878, 2023 (SCI-Expanded)
- XIV. **The role of miRNAs from mesenchymal stem/stromal cells-derived extracellular vesicles in neurological disorders**
Jafarinia M., Farrokhi M. R., Ganjalikhani Hakemi M., Cho W. C.
Human Cell, cilt.36, sa.1, ss.62-75, 2023 (SCI-Expanded)
- XV. **Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia**

chemo-resistance: new insights

Zalpoor H., Bakhtiyari M., Akbari A., Aziziyani F., Shapourian H., Liaghat M., Zare-Badie Z., Yahyazadeh S., Tarhriz V., Ganjalikhani-Hakemi M.

Cell Communication and Signaling, cilt.20, sa.1, 2022 (SCI-Expanded)

- XVI. **Transplantation of human adipose-derived stem cells overexpressing LIF/IFN- β promotes recovery in experimental autoimmune encephalomyelitis (EAE)**
Yousefi M., Nabipour A., Ganjalikhani Hakemi M., Ashja-Arvan M., Amirpour N., Salehi H.
Scientific Reports, cilt.12, sa.1, 2022 (SCI-Expanded)
- XVII. **Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond**
Soltani M., Savvateeva L. V., Ganjalikhani-Hakemi M., Zamyatnin A. A.
Current Drug Targets, cilt.23, sa.11, ss.1072-1084, 2022 (SCI-Expanded)
- XVIII. **Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities**
Rezaei M., Danilova N. D., Soltani M., Savvateeva L. V., Tarasov V. V., Ganjalikhani-Hakemi M., Bazhin A. V., Zamyatnin A. A.
Current Cancer Drug Targets, cilt.22, sa.6, ss.437-453, 2022 (SCI-Expanded)
- XIX. **Quercetin potential effects against SARS-CoV-2 infection and COVID-19-associated cancer progression by inhibiting mTOR and hypoxia-inducible factor-1 α (HIF-1 α)**
Zalpoor H., Bakhtiyari M., Liaghat M., Nabi-Afjadi M., Ganjalikhani-Hakemi M.
Phytotherapy Research, cilt.36, sa.7, ss.2679-2682, 2022 (SCI-Expanded)
- XX. **Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1 α in leukemia progression and mortality**
Zalpoor H., Rezaei M., Yahyazadeh S., Ganjalikhani-Hakemi M.
Human Cell, cilt.35, sa.4, ss.1304-1305, 2022 (SCI-Expanded)
- XXI. **Molecular and immunochemical characterization of Pop n 2: A new allergen of Populus nigra pollen**
Shams M., Assarehzadegan M., Eskandari N., Masjedi M., Kheirandish F., Ghasemi R., Ganjalikhani hakemi M., Varzi A., Safari M., Sohrabi S., et al.
Clinical and Experimental Allergy, cilt.51, sa.12, ss.1613-1623, 2021 (SCI-Expanded)
- XXII. **Mrna-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients**
Bidram M., Zhao Y., Shebardina N. G., Baldin A. V., Bazhin A. V., Ganjalikhany M. R., Zamyatnin A. A., Ganjalikhani-Hakemi M.
Vaccines, cilt.9, sa.10, 2021 (SCI-Expanded)
- XXIII. **Cutting edge: Metabolic immune reprogramming, reactive oxygen species, and cancer**
Aria H., Ghaedrahmati F., Ganjalikhani-Hakemi M.
Journal of Cellular Physiology, cilt.236, sa.9, ss.6168-6189, 2021 (SCI-Expanded)
- XXIV. **Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation**
Katebi A., Varshochian R., Riazi-rad F., Ganjalikhani-Hakemi M., Ajdary S.
Biomedicine and Pharmacotherapy, cilt.137, 2021 (SCI-Expanded)
- XXV. **Modulation of Th17 Proliferation and IL-17A Gene Expression by Acetylated Form of Apigenin in Patients with Multiple Sclerosis**
Rahmati M., Ghannadian S. M., Kasiri N., Ahmadi L., Motedayyen H., Shaygannejad V., Pourazar A., Alsahebfosoul F., Ganjalikhani Hakemi M., Eskandari N.
Immunological Investigations, cilt.50, sa.2-3, ss.216-229, 2021 (SCI-Expanded)
- XXVI. **"NMDA receptor spectrum disorder" in the differential diagnosis of demyelinating disorders of the CNS: optic neuritis and myelitis**
Etemadifar M., Abhari A. P., Sabeti F., Ganjalikhani-Hakemi M., Salari M., Hashemi F., Aghababae A., Khorvash R., Khayati M. H., Nouri H.
Neurological Sciences, cilt.42, sa.1, ss.151-157, 2021 (SCI-Expanded)
- XXVII. **Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma**

- Fathi F., Sanei B., Ganjalikhani Hakemi M., Saidi R. F., Rezaei A.
Canadian Journal of Gastroenterology and Hepatology, cilt.2021, 2021 (SCI-Expanded)
- XXVIII. **Computational study for suppression of CD25/IL-2 interaction**
Dehbashi M., Hojati Z., Motovali-Bashi M., Ganjalikhani-Hakemi M., Shimosaka A., Cho W. C.
Biological Chemistry, cilt.402, sa.2, ss.167-178, 2021 (SCI-Expanded)
- XXIX. **Anti-allergic effects of vitamin E in allergic diseases: An updated review**
Shams M., Jafari R., Eskandari N., Masjedi M., Kheirandish F., Ganjalikhani Hakemi M., Ghasemi R., Varzi A., Sohrabi S., Baharvand P. A., et al.
International Immunopharmacology, cilt.90, 2021 (SCI-Expanded)
- XXX. **The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?**
Ganjalikhani Hakemi M., Jafarina M., Azizi M., Rezaeepoor M., Isayev O., Bazhin A. V.
Frontiers in Oncology, cilt.10, 2020 (SCI-Expanded)
- XXXI. **Impact of IFN- β and LIF overexpression on human adipose-derived stem cells properties**
Ashja-Arvan M., Dehbashi M., Eslami A., Salehi H., Yoosefi M., Ganjalikhani-Hakemi M.
Journal of Cellular Physiology, cilt.235, sa.11, ss.8736-8746, 2020 (SCI-Expanded)
- XXXII. **Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis**
Jafarina M., Alsahebhosoul F., Salehi H., Eskandari N., Azimzadeh M., Mahmoodi M., Asgary S., Ganjalikhani Hakemi M.
Journal of Cellular Physiology, cilt.235, sa.11, ss.8779-8790, 2020 (SCI-Expanded)
- XXXIII. **Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy**
Jafarina M., Alsahebhosoul F., Salehi H., Eskandari N., Ganjalikhani-Hakemi M.
Immunological Investigations, cilt.49, sa.7, ss.758-780, 2020 (SCI-Expanded)
- XXXIV. **Assessment of ability of human adipose derived stem cells for long term overexpression of IL-11 and IL-13 as therapeutic cytokines**
Eslami A., Dehbashi M., Ashja-Arvan M., Salehi H., Azimzadeh M., Ganjalikhani-Hakemi M.
Cytotechnology, cilt.72, sa.5, ss.773-784, 2020 (SCI-Expanded)
- XXXV. **The immunoregulatory and neuroprotective effects of human adipose derived stem cells overexpressing IL-11 and IL-13 in the experimental autoimmune encephalomyelitis mice**
Azimzadeh M., Mahmoodi M., Kazemi M., Hakemi M., Jafarina M., Eslami A., Salehi H., Amirpour N.
International Immunopharmacology, cilt.87, 2020 (SCI-Expanded)
- XXXVI. **Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice**
Azimi-Resketi M., Eskandarian A., Ganjalikhani-Hakemi M., Zohrabi T.
Acta Tropica, cilt.207, 2020 (SCI-Expanded)
- XXXVII. **Quercetin with the potential effect on allergic diseases**
Jafarina M., Sadat Hosseini M., Kasiri N., Fazel N., Fathi F., Ganjalikhani Hakemi M., Eskandari N.
Allergy, Asthma and Clinical Immunology, cilt.16, sa.1, 2020 (SCI-Expanded)
- XXXVIII. **Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine**
Gharibdousti F. S., Gharibdousti F. S., Delshad B. F., Delshad B. F., Falak R., Shayanfar N., Hakemi M., Andalib A., Kardar G. A.
Iranian Journal of Basic Medical Sciences, cilt.23, sa.4, ss.507-514, 2020 (SCI-Expanded)
- XXXIX. **Increased Expression of B Lymphocyte Induced Maturation Protein 1 (BLIMP1) in Patients with Common Variable Immunodeficiency (CVID)**
Farrokhi S., Abbasi-Rad F., Esmaeil N., Sherkat R., Yazdani R., Afshar-Ghasemlou S., Fekrvand S., Ganjalikhani-Hakemi M.
Iranian Journal of Allergy, Asthma and Immunology, cilt.19, sa.4, ss.437-446, 2020 (SCI-Expanded)
- XL. **Correlation of OX40 ligand on B cells with serum total IgE and IL-4 levels by CD4 + T cells in allergic rhinitis**
Fouladi S., Masjedi M., G. Hakemi M., Ghasemi R., Eskandari N.

Allergologia et Immunopathologia, cilt.47, sa.3, ss.234-240, 2019 (SCI-Expanded)

- XLII. **MicroRNA-92a Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis**
Rezaei N., Talebi F., Ghorbani S., Rezaei A., Esmaeili A., Noorbakhsh F., Hakemi M.
Inflammation, cilt.42, sa.1, ss.235-245, 2019 (SCI-Expanded)
- XLIII. **The review of in vitro and in vivo studies over the glycyrrhizic acid as natural remedy option for treatment of allergic asthma**
Fouladi S., Masjedi M., Hakemi M., Eskandari N.
Iranian Journal of Allergy, Asthma and Immunology, cilt.18, sa.1, ss.1-11, 2019 (SCI-Expanded)
- XLIV. **Increased IRF4 expression in isolated B cells from common variable immunodeficiency (CVID) patients**
Afshar-Ghasemlou S., Esmaeil N., Sherkat R., Yazdani R., Abbasi-Rad F., Ganjalikhani-Hakemi M., Rezaei A.
Allergologia et Immunopathologia, cilt.47, sa.1, ss.52-59, 2019 (SCI-Expanded)
- XLV. **Features and roles of T helper 9 cells and interleukin 9 in immunological diseases**
Yazdani R., Shapoori S., Rezaeepoor M., Sanaei R., Ganjalikhani-Hakemi M., Azizi G., Rae W., Aghamohammadi A., Rezaei N.
Allergologia et Immunopathologia, cilt.47, sa.1, ss.90-104, 2019 (SCI-Expanded)
- XLVI. **Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12R β 1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease**
Nekooie-Marnany N., Deswarte C., Ostadi V., Bagherpour B., Taleby E., Ganjalikhani-Hakemi M., Le Voyer T., Rahimi H., Rosain J., Pourmoghadass Z., et al.
Journal of Clinical Immunology, cilt.38, sa.7, ss.787-793, 2018 (SCI-Expanded)
- XLVII. **The In Vitro Impact of Glycyrrhizic Acid on CD4+ T Lymphocytes through OX40 Receptor in the Patients with Allergic Rhinitis**
Fouladi S., Masjedi M., Ghasemi R., G. Hakemi M., Eskandari N.
Inflammation, cilt.41, sa.5, ss.1690-1701, 2018 (SCI-Expanded)
- XLVIII. **Evaluation of the effect of TIM-3 suppression by miR-498 and its effect on apoptosis and proliferation rate of HL-60 cell line**
Moghaddam Y., Andalib A., Mohammad-Ganji M., Homayouni V., Sharifi M., Ganjalikhani-Hakemi M.
Pathology Research and Practice, cilt.214, sa.9, ss.1482-1488, 2018 (SCI-Expanded)
- XLIX. **Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients**
Ghadiri N., Emamnia N., Ganjalikhani-Hakemi M., Ghaedi K., Etemadifar M., Salehi M., Shirzad H., Nasr-Esfahani M. H.
Gene, cilt.659, ss.109-117, 2018 (SCI-Expanded)
- L. **Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level**
Mahmoudi M. B., Abed Khojasteh M., Alsahebhosoul F., Gharibdoost F., Mostafaei S., Ganjalikhani-hakemi M., Mahmoudi M.
Journal of Cosmetic Dermatology, cilt.17, sa.3, ss.549-554, 2018 (SCI-Expanded)
- L. **Semaphorin-3A as An Immune Modulator Is Suppressed by MicroRNA-145-5p**
Rezaeepoor M., Ganjalikhani-hakemi M., Shapoori S., Eskandari N., Sharifi M., Etemadifar M., Mansuorian M.
Cell Journal, cilt.20, sa.1, ss.113-119, 2018 (SCI-Expanded)
- LI. **Silencing of TIM-3 expression by miR-326 affects apoptosis and proliferation of human HL-60 leukemia cell line**
Mohammad-Ganji M., Ganjalikhani-Hakemi M., Homayouni V., Rezaei A., Khanahmad H.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, cilt.28, sa.2, ss.112-122, 2018 (SCI-Expanded)
- LII. **The +4259A>C polymorphism of TIM-3 but not -1637C>T polymorphism of TIM-1 is associated with Multiple sclerosis in Isfahan population**
Pouladian M., Ganjalikhani-Hakemi M., Alsahebhosul F., Homayouni V., Khosravi S., Etemadifar M., Mazrouei F., Salehi R.
Multiple Sclerosis and Related Disorders, cilt.18, ss.152-156, 2017 (SCI-Expanded)
- LIII. **The miR-125a-3p Inhibits TIM-3 Expression in AML Cell Line HL-60 In Vitro**

Emamdoost F., Khanahmad H., Ganjalikhani-hakemi M., Doosti A.

Indian Journal of Hematology and Blood Transfusion, cilt.33, sa.3, ss.342-347, 2017 (SCI-Expanded)

- LIV. **Statistical support for Sema3A and multiple sclerosis**
Rezaeepoor M., Shapoori S., Ganjalikhani-hakemi M., Etemadifar M., Alsahebhosoul F., Eskandari N., Mansourian M.
Gene, cilt.626, ss.87-88, 2017 (SCI-Expanded)
- LV. **Stimulation of camel polyclonal antibody against human T cell immunoglobulin and mucin 3**
Homayouni V., Khanahmad H., Ganjalikhani-Hakemi M., Behdani M., Ghasemi P., Rezaei A.
Iranian Journal of Biotechnology, cilt.15, sa.3, ss.166-171, 2017 (SCI-Expanded)
- LVI. **Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients**
Rezaeepoor M., Shapoori S., Ganjalikhani-hakemi M., Etemadifar M., Alsahebhosoul F., Eskandari N., Mansourian M.
Gene, cilt.610, ss.59-63, 2017 (SCI-Expanded)
- LVII. **Comparison of various classifications for patients with common variable immunodeficiency (CVID) using measurement of B-cell subsets**
Yazdani R., Seify R., Ganjalikhani-Hakemi M., Abolhassani H., Eskandari N., Golsaz-Shirazi F., Ansari-pour B., Salehi E., Azizi G., Rezaei N., et al.
Allergologia et Immunopathologia, cilt.45, sa.2, ss.183-192, 2017 (SCI-Expanded)
- LVIII. **Decreased Expression of B cell Maturation Antigen in Patients with Common Variable Immunodeficiency**
Ansari M., Yazdani R., Sherkat R., Homayouni V., Ganjalikhani-Hakemi M., Rezaei A.
Pediatric, Allergy, Immunology, and Pulmonology, cilt.30, sa.1, ss.7-13, 2017 (SCI-Expanded)
- LIX. **The Effect of Licorice Protein Fractions on Proliferation and Apoptosis of Gastrointestinal Cancer Cell Lines**
Khazraei-Moradian S., Ganjalikhani-Hakemi M., Andalib A., Yazdani R., Arasteh J., Kardar G. A.
Nutrition and Cancer, cilt.69, sa.2, ss.330-339, 2017 (SCI-Expanded)
- LX. **Role of apoptosis in the pathogenesis of common variable immunodeficiency (CVID)**
Ganjalikhani-Hakemi M., Yazdani R., Esmaeili M., Abolhassani H., Rae W., Azizi G., Dizaji M. Z., Shaghghi M., Rezaei A., Abbasi-Rad F., et al.
Endocrine, Metabolic and Immune Disorders - Drug Targets, cilt.17, sa.4, ss.332-340, 2017 (SCI-Expanded)
- LXI. **The increase in protein and plasmid yields of e. Coli with optimized concentration of ampicillin as selection marker**
Feizollahzadeh S., Kouhpayeh S., Rahimmansh I., Khanahmad H., Sabzehei F., Ganjalikhani-Hakemi M., Andalib A., Hejazi Z., Rezaei A.
Iranian Journal of Biotechnology, cilt.15, sa.2, ss.128-134, 2017 (SCI-Expanded)
- LXII. **Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency**
Ganjali Khani Hakemi M.
CLINICAL IMMUNOLOGY, cilt.175, ss.124-132, 2017 (SCI-Expanded)
- LXIII. **Expression of biologically active murine interleukin-18 in Lactococcus lactis**
Feizollahzadeh S., Khanahmad H., Rahimmanesh I., Ganjalikhani-Hakemi M., Andalib A., Sanei M. H., Rezaei A.
FEMS Microbiology Letters, cilt.363, sa.21, 2016 (SCI-Expanded)
- LXIV. **Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)**
Homayouni V., Ganjalikhani-Hakemi M., Rezaei A., Khanahmad H., Behdani M., Lomedasht F. K.
Iranian Journal of Basic Medical Sciences, cilt.19, sa.11, ss.1201-1208, 2016 (SCI-Expanded)
- LXV. **Negative regulation of TIM-3 expression in AML cell line (HL-60) using miR-330-5p**
Fooladinezhad H., Khanahmad H., Ganjalikhani-Hakemi M., Doosti A.
British Journal of Biomedical Science, cilt.73, sa.3, ss.129-133, 2016 (SCI-Expanded)
- LXVI. **Association of TIM-1 5383-5397ins/del and TIM-3 -1541C>T polymorphisms with multiple sclerosis in Isfahan population**
Mazrouei F., Ganjalikhani-Hakemi M., Salehi R., Alesahebhosoul F., Etemadifar M., Pouladian M., Meshkat R., Nekouei S., Zarkesh-Esfahani H., Ziyaee-Ghahnaviyeh M.

- International Journal of Immunogenetics, cilt.43, sa.3, ss.131-134, 2016 (SCI-Expanded)
- LXVII. **Role of apoptosis in common variable immunodeficiency and selective immunoglobulin A deficiency**
Yazdani R, Fatholahi M., Ganjalikhani-Hakemi M., Abolhassani H., Azizi G., Hamid K. M., Rezaei N., Aghamohammadi A.
Molecular Immunology, cilt.71, ss.1-9, 2016 (SCI-Expanded)
- LXVIII. **Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update)**
Yazdani R, Sharifi M., Shirvan A. S., Azizi G., Ganjalikhani-Hakemi M.
Cellular Immunology, cilt.298, sa.1-2, ss.66-76, 2015 (SCI-Expanded)
- LXIX. **Development of a stable cell line, overexpressing human T-cell immunoglobulin mucin 1**
Ebrahimi M., Kazemi T., Ganjalikhani-Hakemi M., Majidi J., Khanahmad H., Rahimmanesh I., Homayouni V., Kohpayeh S.
Iranian Journal of Biotechnology, cilt.13, sa.4, 2015 (SCI-Expanded)
- LXX. **Association analysis of -416 G>C polymorphism of T-cell immunoglobulin and mucin domain-1 gene with asthma in Iran**
Shirzade H., Meshkat R., Ganjalikhani-Hakemi M., Mosayebian A., Ghasemi R., Deress F., Parchami barjui S., Sadri M., Salehi R.
International Journal of Immunogenetics, cilt.42, sa.4, ss.265-269, 2015 (SCI-Expanded)
- LXXI. **miR-141 and miR-200a, revelation of new possible players in modulation of Th17/Treg differentiation and pathogenesis of multiple sclerosis**
Naghavian R., Ghaedi K., Kiani-Esfahani A., Ganjalikhani-Hakemi M., Etemadifar M., Nasr-Esfahani M. H.
PLoS ONE, cilt.10, sa.5, 2015 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Nanoparticles as Potent Agents for Treatment of Schistosoma Infections: A Systematic Review**
Shakib P., Zivdari M., Khalaf A. K., Marzban A., Ganjalikhani-Hakemi M., Parvaneh J., Mahmoudvand H., Cheraghipour K.
Current Therapeutic Research - Clinical and Experimental, cilt.99, 2023 (ESCI)
- II. **Evaluation of Silencing Effect of miR-133a-5p Mimic on TIM-3 Expression in AML (HL-60) Cell Line**
Hojati Z., Ganjalikhani-Hakemi M., Ameri M., Alimohammadi-Jelodar S. F., Dehbashi M., Mohammad Ganji M., Homayouni V., Khanahmad H.
Indian Journal of Clinical Biochemistry, cilt.35, sa.3, ss.359-366, 2020 (ESCI)
- III. **The Upregulation of hsa-mir-181b-1 and Downregulation of Its Target CYLD in the Late-Stage of Tumor Progression of Breast Cancer**
Andalib A., Rashed S., Dehbashi M., Hajati J., Noorbakhsh F., Ganjalikhani-Hakemi M.
Indian Journal of Clinical Biochemistry, cilt.35, sa.3, ss.312-321, 2020 (ESCI)
- IV. **Outcome of corneal collagen cross-linking in keratoconus: Introducing the predictive factors**
Peyman A., Feizi A., Ganjalikhani-Hakemi M., Hosseini-Nasab F., Pourazizi M.
Journal of Current Ophthalmology, cilt.32, sa.1, ss.19-25, 2020 (ESCI)
- V. **Optimization of in vitro expansion and activation of human natural killer cells against breast cancer cell line**
Peighambarzadeh F., Najafalizadeh A., Esmaeil N., Rezaei A., Ashrafi F., Hakemi M.
AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY, cilt.12, ss.17-23, 2020 (Scopus)
- VI. **Negative regulation of semaphorin-3A expression in peripheral blood mononuclear cells using microRNA-497-5P**
Shapoori S., Ganjalikhani-Hakemi M., Rezaeepoor M., Alsahebhosoul F., Khosravi S., Etemadifar M., Mansourian M.
Iranian Journal of Medical Sciences, cilt.44, sa.4, ss.325-333, 2019 (Scopus)
- VII. **Integral membrane protein expression of human CD25 on the cell surface of HEK293 cell line: The available cellular model of CD25 positive to facilitate in vitro developing assays**

Dehbashi M., Hojati Z., Motovali-Bashi M., Ganjalikhani-Hakemi M., Shimosaka A.

Biomolecular Concepts, cilt.10, sa.1, ss.150-159, 2019 (Scopus)

VIII. **Exons analysis of interferon-gamma receptor 1 gene in patients with Mendelian susceptibility to mycobacterial diseases (MSMD) in the central region of Iran**

Sherkat R., Yaran M., Nekooei N., Talebi E., Rahimi H., Bagherpoor B., Behnam M., Rostami S., Najafi S., Nourimahdavi A., et al.

Journal of Isfahan Medical School, cilt.36, sa.503, ss.1349-1354, 2019 (Scopus)

IX. **Recurrent vulvovaginal candidiasis: Could it be related to cell-mediated immunity defect in response to Candida antigen?**

Talaei Z., Sheikhabaei S., Ostadi V., Hakemi M., Meidani M., Naghshineh E., Yaran M., Naeini A. E., Sherkat R.

International Journal of Fertility and Sterility, cilt.11, sa.3, ss.134-141, 2017 (Scopus)

X. **Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line**

Dastjerdi M. N., Kavooosi F., Valiani A., Esfandiari E., Sanaei M., Sobhanian S., Hakemi M., Mobarakian M.

International Journal of Preventive Medicine, cilt.2015-june, 2015 (Scopus)

XI. **Molecular cloning and expression of novel fibroblast growth factor-2 conjugated with immunodominant domains of pseudomonas exotoxin**

Haghighatfard H., Samaei N. M., Farazmandfar T., Hakemi M., Yamchi A., Jadidi-Niaragh F., Yazdani Y.

Biomedical and Pharmacology Journal, cilt.8, sa.2, ss.1195-1200, 2015 (Scopus)

Metrikler

Yayın: 82

Atf (Scopus): 1001

H-İndeks (Scopus): 17